Zogenix Company Profile (NASDAQ:ZGNX)

About Zogenix (NASDAQ:ZGNX)

Zogenix logoZogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Medical Devices
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ZGNX
  • CUSIP: 98978L10
  • Web: www.zogenix.com
  • Market Cap: $1.25053 billion
  • Outstanding Shares: 24,841,000
Average Prices:
  • 50 Day Moving Avg: $24.71
  • 200 Day Moving Avg: $15.68
  • 52 Week Range: $7.50 - $41.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.73
  • P/E Growth: -0.42
Sales & Book Value:
  • Annual Revenue: $27.38 million
  • Price / Sales: 36.06
  • Book Value: $3.20 per share
  • Price / Book: 12.42
  • EBITDA: ($72,480,000.00)
  • Net Margins: -309.76%
  • Return on Equity: -70.75%
  • Return on Assets: -35.37%
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 3.59%
  • Quick Ratio: 3.48%
  • Average Volume: 1.46 million shs.
  • Beta: 2.06
  • Short Ratio: 15.72

Frequently Asked Questions for Zogenix (NASDAQ:ZGNX)

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.01. The company earned $7.10 million during the quarter, compared to the consensus estimate of $3.48 million. Zogenix had a negative return on equity of 70.75% and a negative net margin of 309.76%. Zogenix's quarterly revenue was up 238.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.76) earnings per share. View Zogenix's Earnings History.

When will Zogenix make its next earnings announcement?

Zogenix is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Zogenix.

Where is Zogenix's stock going? Where will Zogenix's stock price be in 2017?

5 analysts have issued twelve-month price objectives for Zogenix's stock. Their forecasts range from $28.00 to $55.00. On average, they expect Zogenix's share price to reach $46.00 in the next year. View Analyst Ratings for Zogenix.

What are analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:

  • 1. Mizuho analysts commented, "We view the readout as impressive, but expect in real world application, a small percentage (~10-15%) of patients may not tolerate the therapy well. We further believe ZX-008 has better efficacy than GW Pharma’s competing drug, Epidiolex (GWPH, non-rated) NDA filing expected 2H2018. Zogenix’s pivotal phase III program for ZX008 is in DS comprises Study 1 and 1504. Data from both trials will be used in the NDA registration for the US." (9/29/2017)
  • 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (9/1/2017)
  • 3. Aegis analysts commented, "adjunctive anti-epileptic therapy."Yang comments, "Study 1504 - a two cohort study to assess ZX008 as an adjunctive antiepileptic therapy. Designed as a multi-center study, 1504 is portioned into two cohorts that are a part of the phase III program for ZX008 in Dravet Syndrome. The first cohort assessed the pharmacokinetics and safety profile of ZX008 (fenfluramine hydrochloride), valproate, and clobazam when administered with stiripentol. In assessing these two aspects, cohort 1 served its primary purpose - identify the appropriate dosage of ZX008 to be used in the second cohort of the trial (0.5 mg/kg/day). Cohort 2 is designed as a double-blind, placebocontrolled trial randomizing 70 patients 1:1 (ZX008:placebo) after a 6 week baseline observation period. After a 3 week titration period, patients will receive either 0.5 mg/kg/day of ZX008 or equivalent placebo before being assessed at 12 weeks. The primary endpoint for cohort 2 is change from baseline in frequency of convulsive seizures, the same as study 1501 and 1502. All patients enrolled in the "stiripentol incomplete responder" trial will remain on their stable stiripentol drug regimen in addition to receiving either ZX008 or placebo." (2/14/2017)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:

  • Cam L. Garner, Independent Chairman of the Board
  • Stephen J. Farr Ph.D., President, Chief Executive Officer, Director
  • Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary
  • Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer
  • Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer
  • Thierry J P Darcis, Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
  • James B. Breitmeyer M.D., Ph.D., Director
  • Roger L. Hawley, Director
  • Erle T. Mast, Independent Director
  • Mark C. Wiggins, Independent Director

How do I buy Zogenix stock?

Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of Zogenix stock can currently be purchased for approximately $39.75.

MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zogenix (NASDAQ:ZGNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $46.00 (15.72% upside)
Consensus Price Target History for Zogenix (NASDAQ:ZGNX)
Price Target History for Zogenix (NASDAQ:ZGNX)
Analysts' Ratings History for Zogenix (NASDAQ:ZGNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/2/2017Leerink SwannReiterated RatingOutperform -> Outperform$20.00 -> $50.00HighView Rating Details
9/29/2017Stifel NicolausReiterated RatingBuy$26.00 -> $55.00N/AView Rating Details
9/29/2017William BlairUpgradeMarket Perform -> OutperformN/AView Rating Details
9/29/2017MizuhoReiterated RatingBuy -> Buy$28.00 -> $51.00N/AView Rating Details
3/11/2017AegisReiterated RatingBuy$28.00N/AView Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
10/21/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$23.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Zogenix (NASDAQ:ZGNX)
Earnings by Quarter for Zogenix (NASDAQ:ZGNX)
Earnings History by Quarter for Zogenix (NASDAQ ZGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.97)N/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.90)$3.48 million$7.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.88)($0.85)$4.23 million$2.70 millionViewListenView Earnings Details
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$11.50 million$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Zogenix (NASDAQ:ZGNX)
2017 EPS Consensus Estimate: ($2.62)
2018 EPS Consensus Estimate: ($3.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.85)($0.85)($0.85)
Q3 20172($0.99)($0.93)($0.96)
Q4 20171($0.81)($0.81)($0.81)
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.85)($0.85)($0.85)
Q3 20181($0.90)($0.90)($0.90)
Q4 20181($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)


Dividend History for Zogenix (NASDAQ:ZGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zogenix (NASDAQ:ZGNX)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 68.71%
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)
Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Life Sciences Maste PerceptiveMajor ShareholderBuy300,000$37.50$11,250,000.00View SEC Filing  
9/29/2017Life Sciences Maste PerceptiveMajor ShareholderBuy222,055$32.83$7,290,065.65View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy175,653$14.45$2,538,185.85View SEC Filing  
3/16/2017Renee P TannenbaumDirectorBuy5,000$11.00$55,000.00View SEC Filing  
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.00View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.00View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Zogenix (NASDAQ:ZGNX)
Latest Headlines for Zogenix (NASDAQ:ZGNX)
finance.yahoo.com logoHigh Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
finance.yahoo.com - October 19 at 10:34 AM
finance.yahoo.com logoETFs with exposure to Zogenix, Inc. : October 16, 2017
finance.yahoo.com - October 17 at 9:32 AM
finance.yahoo.com logoInterim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
finance.yahoo.com - October 16 at 8:22 AM
seekingalpha.com logoDaily Insider Ratings Round Up 10/3/17: ZGNX, SOR - Seeking Alpha
seekingalpha.com - October 6 at 3:36 PM
finance.yahoo.com logoETFs with exposure to Zogenix, Inc. : October 5, 2017
finance.yahoo.com - October 6 at 10:05 AM
finance.yahoo.com logoZogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 6 at 10:05 AM
americanbankingnews.com logoQ3 2017 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By Leerink Swann
www.americanbankingnews.com - October 6 at 7:14 AM
seekingalpha.com logoZogenix closes equity offering, raises almost $289M; shares down 2% after hours
seekingalpha.com - October 5 at 4:47 PM
seekingalpha.com logoZogenix: Investors Bet Heavy On ZX008 For Dravet Syndrome
seekingalpha.com - October 4 at 6:01 PM
finance.yahoo.com logoZogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : October 2, 2017
finance.yahoo.com - October 4 at 6:01 PM
finance.yahoo.com logoZogenix Prices Public Offering of Common Stock
finance.yahoo.com - October 4 at 6:01 PM
finance.yahoo.com logoA Drug That May Be Better Than Marijuana Sent This Company's Stock Soaring 196% in September
finance.yahoo.com - October 4 at 1:00 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: GW Pharmaceuticals and Zogenix
finance.yahoo.com - October 4 at 1:00 PM
finance.yahoo.com logoZogenix, Inc. :ZGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 1:00 PM
nasdaq.com logoImplied Volatility Surging for Zogenix (ZGNX) Stock Options - Nasdaq
www.nasdaq.com - October 3 at 4:30 PM
seekingalpha.com logoZogenix Brings About Rivalry For Rare Epilepsy Drug - Seeking Alpha
seekingalpha.com - October 3 at 4:30 PM
finance.yahoo.com logoImplied Volatility Surging for Zogenix (ZGNX) Stock Options
finance.yahoo.com - October 3 at 4:30 PM
americanbankingnews.com logoLife Sciences Maste Perceptive Acquires 300,000 Shares of Zogenix, Inc. (ZGNX) Stock
www.americanbankingnews.com - October 3 at 4:28 PM
americanbankingnews.com logoInsider Buying: Zogenix, Inc. (ZGNX) Major Shareholder Purchases 222,055 Shares of Stock
www.americanbankingnews.com - October 3 at 10:18 AM
fool.com logoHow Risky Is GW Pharmaceuticals Stock After Zogenix's Big News?
www.fool.com - October 3 at 7:42 AM
fool.com logoZogenix Soars 10% Today Despite Diluting Investors
www.fool.com - October 2 at 3:24 PM
feeds.benzinga.com logoWhat Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
feeds.benzinga.com - October 2 at 2:14 PM
americanbankingnews.com logoLeerink Swann Boosts Zogenix, Inc. (ZGNX) Price Target to $50.00
www.americanbankingnews.com - October 2 at 9:12 AM
americanbankingnews.com logoQ1 2018 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By William Blair
www.americanbankingnews.com - October 2 at 4:56 AM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 2 at 2:38 AM
globenewswire.com logoZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome - GlobeNewswire (press release)
globenewswire.com - October 1 at 5:40 AM
seekingalpha.com logoZogenix' ZX008 Is The Real Deal - Seeking Alpha
seekingalpha.com - September 30 at 9:10 PM
fool.com logo3 Biotech Stocks That Soared This Week: Are They Buys?
www.fool.com - September 30 at 11:35 AM
marketwatch.com logoUPDATE: Zogenix stock rockets 195% premarket on news of positive epilepsy drug trial
www.marketwatch.com - September 30 at 11:00 AM
streetinsider.com logoUPDATE: William Blair Upgrades Zogenix, Inc. (ZGNX) to Outperform - StreetInsider.com
www.streetinsider.com - September 29 at 10:29 PM
streetinsider.com logoZogenix (ZGNX) Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Met Primary Objective
www.streetinsider.com - September 29 at 5:24 PM
nasdaq.com logoZogenix Inc. (ZGNX) Has Soared To A New High On Phase 3 Study Results
www.nasdaq.com - September 29 at 5:24 PM
finance.yahoo.com logoZogenix (ZGNX) Stock Skyrocketed Over 170% Today: Here's Why
finance.yahoo.com - September 29 at 5:24 PM
feeds.benzinga.com logoMid-Afternoon Market Update: Envirostar Drops After Fiscal 2017 Results; Zogenix Shares Spike Higher
feeds.benzinga.com - September 29 at 2:37 PM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Lifted to "Outperform" at William Blair
www.americanbankingnews.com - September 29 at 1:31 PM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - September 29 at 1:31 PM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - September 29 at 11:30 AM
fool.com logoWhy Zogenix Inc. Stock More Than Doubled Today
www.fool.com - September 29 at 10:56 AM
cnbc.com logoA biotech stock just instantly doubled in value on positive epilepsy drug test results
www.cnbc.com - September 29 at 9:25 AM
seekingalpha.com logoGW Pharma slips 15% premarket on Zogenix's successful late-stage study of ZX008 in Dravet
seekingalpha.com - September 29 at 8:41 AM
seekingalpha.com logoZogenix trading halted pending news
seekingalpha.com - September 29 at 7:10 AM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Expected to Post Earnings of -$0.97 Per Share
www.americanbankingnews.com - September 19 at 2:26 PM
nasdaq.com logoZogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2% - Nasdaq
www.nasdaq.com - September 12 at 12:38 PM
zacks.com logoZogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2%
www.zacks.com - September 11 at 8:58 AM
thestreet.com logoNotable Friday Option Activity: URI, ZGNX, GTN
www.thestreet.com - September 9 at 10:25 AM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 7 at 2:46 AM
streetinsider.com logoUPDATE: Mizuho Securities Starts Zogenix, Inc. (ZGNX) at Buy - StreetInsider.com
www.streetinsider.com - September 6 at 8:30 PM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Coverage Initiated by Analysts at Mizuho
www.americanbankingnews.com - September 6 at 5:18 PM
seekingalpha.com logoZogenix breaks out of consolidation on high volume; shares up 15% ahead of data readout on lead candidate ZX008
seekingalpha.com - September 6 at 11:46 AM
finance.yahoo.com logo3 Biotech Stocks That Could Soar in September
finance.yahoo.com - August 27 at 8:28 AM



Zogenix (ZGNX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.